Omalizumab: a review of its use in patients with severe persistent allergic asthma (Q38118172)

29 August 2017

Omalizumab: a review of its use in patients with severe persistent allergic asthma (English)

1 reference

29 August 2017

1 reference

1

Kate McKeage

1 reference

29 August 2017

1 July 2013

1 reference

29 August 2017

1 reference

29 August 2017

73

1 reference

29 August 2017

11

1 reference

29 August 2017

1197-1212

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-013-0085-4

29 August 2017

0 references

cites work

Omalizumab: a review of its use in the treatment of allergic asthma

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Effects of omalizumab on markers of inflammation in patients with allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Omalizumab inhibits acceleration of FcεRI-mediated responsiveness of immature human mast cells by immunoglobulin E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Omalizumab-induced decrease of FcξRI expression in patients with severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Effect of omalizumab on peripheral blood eosinophilia in allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Monitoring free serum IgE in severe asthma patients treated with omalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Can anti-IgE therapy prevent airway remodeling in allergic asthma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Omalizumab is effective in the long-term control of severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

The oral corticosteroid-sparing effect of omalizumab in children with severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Omalizumab in patients with severe asthma: the XCLUSIVE study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Development and validation of a questionnaire to measure asthma control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Improvement in quality of life with omalizumab in patients with severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

"Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Italian real-life experience of omalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: Results from a large cohort of patients with severe uncontrolled asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Safety and tolerability of omalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Omalizumab: Practical considerations regarding the risk of anaphylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Omalizumab and the risk of malignancy: results from a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Churg-strauss syndrome in patients treated with omalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

The recovery-ELISA--a novel assay technique to monitor therapy with humanized antibodies: the example of omalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Omalizumab: Anti-IgE therapy in allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0085-4

Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy

21 January 2018

1 reference

12 December 2020

Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma

1 reference

12 December 2020

RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy

1 reference

12 December 2020

Airway inflammation and eotaxin in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy

1 reference

12 December 2020

Development of the asthma control test: a survey for assessing asthma control

1 reference

12 December 2020

Development and validation of the Mini Asthma Quality of Life Questionnaire

1 reference

12 December 2020

Omalizumab improves asthma-related quality of life in patients with severe allergic asthma

1 reference

12 December 2020

Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs

1 reference

12 December 2020

Predicting and evaluating response to omalizumab in patients with severe allergic asthma

1 reference

12 December 2020

Extent of uncontrolled disease and associated medical costs in severe asthma--a PHARMO study

1 reference

12 December 2020

Mechanisms of action of anti-immunoglobulin E therapy.

1 reference

12 December 2020

After 6 years with Xolair; a 3-year withdrawal follow-up

1 reference

12 December 2020

Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma

1 reference

12 December 2020

Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma

1 reference

12 December 2020

Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma

1 reference

12 December 2020

Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients.

1 reference

12 December 2020

Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey

1 reference

12 December 2020

Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma

1 reference

12 December 2020

10.1007/S40265-013-0085-4

Identifiers

DOI

1 reference

PubMed ID

23812924

Dimensions Publication ID

29 August 2017

0 references

1 reference

PubMed ID

23812924